Live birth following day surgery reversal of female sterilisation in women older than 40 years: a realistic option in Australia?

OBJECTIVE: To determine the live birth rate following surgical reversal of sterilisation in women aged 40 years and older. DESIGN: Retrospective cohort study of pregnancy outcome following day surgery microsurgical reversal of sterilisation performed by two reproductive microsurgeons in the private sector. SETTING AND PATIENTS: 47 patients (aged 40 years or older) who had reversal of sterilisation performed between 1997 and 2005 in Adelaide, South Australia (n=35), or the Infertility Centre of St Louis, Missouri, USA (n=12). MAIN OUTCOME MEASURES: Independently audited live birth surviving the neonatal period. RESULTS: Of the 47 patients on whom follow-up was obtainable from the two centres, 19 (40%) had a live birth, 7 had had only a first trimester miscarriage at the time of follow-up, and 21 (44%) had failed to conceive. Age at conception ranged between 40 and 47 years. Two women had two live births following surgery. The total direct costs (Australian dollars, adjusted to 2005) in Australia were $4850 per treatment, and $11,317 per live birth. The corresponding direct cost of a single cycle of in-vitro fertilisation (IVF) in Australia has been estimated at $6940, with a cost per live birth of $97 884 for women aged 40-42 years and $182,794 for older women. CONCLUSION: Previously sterilised women wanting further pregnancy should be offered tubal surgery as an alternative to IVF, as it offers them the opportunity to have an entirely natural pregnancy. In settings where IVF is financially supported by government agencies or insurance, tubal reversal is a highly cost-effective strategy for the previously fertile woman.

Infertility caused by HCG autoantibody.

An anti-hCG autoantibody was found in a patient with a 9-yr history of secondary infertility. Although the patient had regular menstrual cycles, had conceived spontaneously, and had good hormonal and follicular responses to gonadotropic stimulation regimens during the in vitro fertilization work-up, she presented with apparent recurrent pregnancy loss associated with prolonged raised hCG levels. Initially the presence of a high mol wt hCG complex was demonstrated in the serum by gel chromatography. The binding of [(125)I]recombinant hCG to a serum sample and subsequently to the affinity-purified IgG from the same sample revealed the presence of an hCG antibody. The antiserum was shown to be specific, with a low affinity (K(a), 1.4 x 10(6) liters/mol), but a high capacity (418 nmol/liter), for hCG. Cross-reaction with recombinant human FSH, recombinant human LH, hCG alpha, and hCG beta were low (<0.019%, 0.021%, 0.039%, and 0.006%, respectively). In addition, heat-inactivated serum and the affinity-purified IgG were shown to inhibit the action of hCG in an in vitro bioassay. We suggest that the persisting titer of the antibody to be responsible for the patient's infertility.